|Bid||89.67 x 800|
|Ask||89.79 x 300|
|Day's Range||89.21 - 92.41|
|52 Week Range||74.60 - 106.27|
|Beta (3Y Monthly)||1.29|
|PE Ratio (TTM)||18.34|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||1.60 (1.80%)|
|1y Target Est||94.74|
Shares of AmerisourceBergen Corporation (NYSE:ABC) will begin trading ex-dividend in 4 days. To qualify for the dividend check of US$0.40 per share, investors must have owned the shares prior to Read More...
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We’ll show how you can use AmerisourceBergen Corporation’s (NYSE:ABC) P/E ratio to Read More...
Shares of AmerisourceBergen Corp. tumbled 9.1% in morning trade Tuesday, after the drug company reported fiscal fourth-quarter earnings and revenue that just topped expectations but provided a downbeat profit outlook, citing a "potential sizable headwind" for its PharMEDium business. The company also disclosed in filing with the Securities and Exchange Commission that production at PharMEDium's facilities remains suspended, while Leerink analyst David Larsen said commercial operations were previously expected to begin in September, as the company waited for feedback from the Food and Drug Administration. Earlier Tuesday, the company reported fourth-quarter net income of $233.3 million, or $1.07 a share, compared with a loss of $344.6 million, or $1.58 a share, in the same period a year ago. Adjusted earnings per share came to $1.45, above the FactSet consensus of $1.44, but the fiscal 2019 adjusted EPS outlook of $6.65 to $6.95 was below expectations of $7.11. The stock has lost 2.0% over the past three months, while the SPDR Health Care Select Sector ETF has gained 0.3% and the S&P 500 has lost 3.6%.
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q4.
Steve Collis has been the CEO of AmerisourceBergen Corporation (NYSE:ABC) since 2011. First, this article will compare CEO compensation with compensation at other large companies. After that, we will consider Read More...
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 0.69% and -0.53%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Check out the companies making headlines before the bell: Eli Lilly LLY – The drug giant reported adjusted quarterly profit of $1.39 per share, four cents above estimates, with revenue also beating Street forecasts.
On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had net income of $1.07. Earnings, adjusted for one-time gains and costs, were $1.45 per share. The results surpassed Wall Street ...
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.
NEW YORK, Oct. 30, 2018 -- Levi & Korsinsky announces it has commenced an investigation of AmerisourceBergen Corporation (NYSE: ABC) concerning possible violations of.
AmerisourceBergen Corporation (NYSE:ABC) shareholders, and potential investors, need to understand how much cash the business makes from its core operational activities, as well as how much is invested back into Read More...
NEW YORK, Oct. 30, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of AmerisourceBergen Corporation (NYSE:.
AmerisourceBergen (ABC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zamansky LLC announces that it is investigating AmerisourceBergen Corporation (ABC) (“AmerisourceBergen” or the “Company”) for potential breaches of fiduciary duties by its senior officers and board of directors. If you are a shareholder of AmerisourceBergen who still holds your shares, please contact our firm for information. On October 1, 2018, the Company announced that it will pay $625 million to resolve civil fraud charges over its sales of refilled syringes to cancer patients, double-billing and providing kick-backs to doctors.
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is investigating whether certain directors and officers of AmerisourceBergen Corporation (“AmerisourceBergen” or the “Company”) (ABC) breached their fiduciary duties to the Company and its shareholders. If you are an AmerisourceBergen shareholder, you are encouraged to contact Scott+Scott for additional information.